Lab & Diagnostics MD $25K – $100K Reviewed

Custom MHC Class II HLA-DP Xynapse and Dextramer R

HHS

BETHESDA, MD

MHC Class II reagents HLA-DP dextramers neoantigen validation liver cancer research $25K – $100K

Posted Jul 14, 2026

Due Jul 22, 2026

Description

The HHS procurement seeks custom MHC Class II HLA-DP Xynapse and Dextramer reagents for validating neoantigens in liver cancer studies. These specialized immunological tools will enable detailed analysis of T-cell responses and antigen presentation. Biotechnology firms and reagent manufacturers experienced in custom MHC multimer and HLA-specific product development are likely bidders.

A strong match for healthcare vendors

Curated for medical & healthcare suppliers

Why we classified this as medical

Title and description explicitly name custom MHC Class II HLA-DP Xynapse and Dextramer reagents procured for liver cancer neoantigen validation, which is laboratory/diagnostic reagent work directly supporting clinical cancer research.

View Original Source

Save for Later

Send to Pipeline